SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

Medical Radiology and Radiation Safety. 2016. Vol. 61. No. 1. P. 47-59

REVIEW

G.E. Roytberg1, S.V. Usychkin1, A.V. Boiko2

Extreme Hypofractionated external-Beam radiotherapy for Prostate Cancer

1. JSC “Medicina”, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; 2. P.A.Herzen Moscow Scientific-Research Oncological Institute, Moscow, Russia

ABSTRACT

Hypofractionation is one of the approaches in the non-classical fractionation of prostate cancer external-beam radiotherapy. The purpose of hypofractionation is not only to make the treatment more comfortable for the patient (less daily visits to the treatment center) and more cost-effective but also to increase the local tumor control as well. High dose per fraction increases a biologically effective dose for prostate adenocarcinoma cells and works as a biological radiosensitizer while isoeffective dose for normal tissues remains unchanged. In 80-90 % of patients with localized prostate cancer treated with extremely hypofractionated radiotherapy (7 to 8 Gy dose per fraction, 5 fractions to the total dose of 35-40 Gy) a permanent biochemical tumor control is achieved. The modern high-precision treatment planning and treatment delivery techniques (IMRT, VMAT) as well as on-line target tracking and image guidance (IGRT) coupled with additional systems of internal prostate immobilization (endorectal balloons and «spacers» inserted between prostate and rectal wall) are prerequisite conditions for extreme hypofractionated radiotherapy. Completed recently multiple studies of phase 2 have demonstrated that extremely hypofractionated prostate radiotherapy did not increase the rate of serious late toxicity if it is performed in the clinics with high level of modern technical equipment Image-Guided Radiotherapy. For this reason it can be used as an alternative to the conventionally fractionated radiotherapy.

Key words: external-beam radiotherapy, extreme fractionation, prostate cancer, hypofractiotion

REFERENCES

  1. Tarinskii V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost' i smertnost'). Moscow: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii. 2014. 250 p. (In Russ.).
  2. D’Amico A.V., Whittington R., Malkowicz S.B. et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002. Vol. 95. No. 2. P. 281-286.
  3. D’Amico A.V., Whittington R., Malkowicz S.B. et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 1999. Vol. 17. No. 1. P. 168-172.
  4. D’Amico A.V. Prostate cancer: where we have been. where we are. and where we are going. Semin Radiat. 2013. Vol. 23. No. 3. P. 155-156.
  5. Peeters S.T., Heemsbergen W.D., Koper P.C. et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 2006. Vol. 24. No. 13. P. 1990-1996.
  6. Pollack A., Zagars G.K., Starkschall G. et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int. J. Radiat. Biol. Phys. 2002. Vol. 53. No. 5. P. 1097-1105.
  7. Zietman A.L., DeSilvio M.L., Slater J.D. et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005. Vol. 294. No. 10. P. 1233-1239.
  8. Spratt D.E., Pei X., Yamada J. et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int. J. Radiat. Biol. Phys. 2013. Vol. 85. No. 3. P. 686-692.
  9. Dar'yalova S.L., Boiko A.V., Alekseev B.Ya., Grishina Yu.A. Metodika i rezul'taty luchevoi terapii raka predstatel'noi zhelezy. Ross. onkol. zhurnal. 2006. No. 6. P. 9-13. (In Russ.).
  10. Boiko A.V., Chernichenko A.V., Dar'yalova S.L., Meshcheryakova I.A., Ter-Arutyunyants S.A. Netraditsionnoe fraktsionirovanie dozy. V sb. «Materialy V Rossiiskoi onkologicheskoi konferentsii». 2001.
  11. Chernichenko A.V., Boiko A.V., Morozova S.V. et al. Termoradioterapiya raka predstatel'noi zhelezy. Ross. onkol. zhurnal. 2009. No. 3. P. 9-12. (In Russ.).
  12. Miles E.F., Lee W.R. Hypofractionation for prostate cancer: a critical review. Semin. Radiat. Oncol. 2008. Vol. 18. No. 1. P. 41-47.
  13. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. 1999. Vol. 43. No. 5. P. 1095-1101.
  14. Vogelius I.R., Bentzen S.M. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news. good news. or no news?. Int. J. Radiat. Oncol. Phys. 2013. Vol. 85. No. 1. P. 89-94.
  15. Fowler J.F., Toma-Dasu I., Dasu A. Is the alpha/beta ratio for prostate tumours really low and does it vary with the level of risk at diagnosis? Anticancer Res. 2013. Vol. 33. No. 3. P. 1009-1011.
  16. Tree A.C., Khoo V.S., van As N.J. et al. Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models? Clin. (R. Coll. Radiol.). 2014. Vol. 26. No. 4. P. 216-229.
  17. Kupelian P.A., Willoughby T.R., Reddy C.A. et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Biol. Phys. 2007. Vol. 68. No. 5. P. 1424-1430.
  18. Yeoh E.E., Botten R.J., Butters J. et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int. J. Radiat. Biol. Phys. 2011. Vol. 81. No. 5. P. 1271-1278.
  19. Dearnaley D., Syndikus I., Sumo G. et al. Conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomized controlled trial. Lancet Oncol. 2012. Vol. 13. No. 1. P. 43-54.
  20. Arcangeli G., Saracino B., Gomellini S. et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int. J. Radiat. Biol. Phys. 2010. Vol. 78. No. 1. P. 11-18.
  21. Arcangeli S., Strigari L., Gomellini S. et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int. J. Radiat. Biol. Phys. 2012. Vol. 84. No. 5. P. 1172-1178.
  22. Arcangeli G., Fowler J., Gomellini S. et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011. Vol. 79. No. 4. P. 1013-1021.
  23. Arcangeli S., Scorsetti M., Alongi F. Will SBRT replace conventional radiotherapy in patients with low intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol. 2012. Vol. 84. No. 1. P. 101-108.
  24. Buyyounouski M.K., Price R.A., , Harris E.E. et al. Stereotactic body radiotherapy for primary management of early-stage. low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 76. No. 5. P. 1297-1304.
  25. Ishiyama H., Teh B.S., Lo S.S. et al. Stereotactic body radiation therapy for prostate cancer. Future Oncol. 2011. Vol. 7. No. 9. P. 1077-1086.
  26. Fuks Z., Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005. Vol. 8. No. 2. P. 89-91.
  27. Collins C.D., Lloyd-Davies R.W., Swan A.V. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin. (R. Coll. Radiol.). 1991. Vol. 3. No. 3. P. 127-132.
  28. Martinez A.A., Demanes J., Vargas C. et al. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Amer. J. Clin. 2010. Vol. 33. No. 5. P. 481-488.
  29. King C.R., Lehmann J., Adler J.R. et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol. Cancer Res. Treat. 2003. Vol. 2. No. 1. P. 25-30.
  30. Fuller D.B., Naitoh J., Lee C. et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int. J. Radiat. Biol. Phys. 2008. Vol. 70. No. 5. P. 1588-1597.
  31. King C.R., Brooks J.D., Gill H. et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int. J. Radiat. Biol. Phys. 2009. Vol. 73. No. 4. P. 1043-1048.
  32. King C.R., Brooks J.D., Gill H. et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int. J. Radiat. Biol. Phys. 2012. Vol. 82. No. 2. P. 877-882.
  33. Katz A.J., Santoro M., Diblasio F. et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat. 2013. Vol. 8. No. 1. P. 1-8.
  34. King C .R., Freeman D., Kaplan I. et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother. Oncol. 2013. Vol. 109. No. 2. P. 217-221.
  35. Madsen B.L., Hsi R.A., Pham H.T. et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP). 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Biol. Phys. 2007. Vol. 67. No. 4. P. 1099-1105.
  36. Friedland J.L., Freeman D.E., Masterson-McGary M.E. et al. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol. Cancer Res. Treat. 2009. Vol. 8. No. 5. P. 387-392.
  37. Boike T.P., Lotan Y., Cho L.C. et al. Phase I dose-escalation study of stereotactic body radiation therapy for lowand intermediate-risk prostate cancer. J. Clin. Oncol. 2011. Vol. 29. No. 15. P. 2020-2026.
  38. Kang J.K., Cho C.K., Choi C.W. et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori. 2011. Vol. 97. No. 1. P. 43-48.
  39. McBride S.M., Wong D.S., Dombrowski J.J. et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012. Vol. 118. No. 15. P. 3681-3690.
  40. Bolzicco G., Favretto M.S., Satariano N. et al. A singlecenter study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 2013. Vol. 13. No. 1. P. 1-8.
  41. Chen L.N., Suy S., Uhm S. et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat. 2013. Vol. 8. No. 1. P. 1-10.
  42. Aluwini S., van Rooij P., Hoogeman M. et al. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat. 2013. Vol. 8. No. 1. P. 1-7.
  43. Oliai C., Lanciano R., Sprandio B. et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J. Radiat. Oncol. 2013. Vol. 2. No. 1. P. 63-70.
  44. Loblaw A., Cheung P., D’Alimonte L. et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity. biochemical. and pathological outcomes. Radiother. 2013. Vol. 107. No. 2. P. 153-158.
  45. Tree A., Aluwini S., Bryant H. et al. Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence). Int. J. Radiat. Oncol. Biol. Phys. 2013. Vol. 87. No. 2. P. S365.
  46. Mohler J.L., Kantoff P.W., Armstrong A.J. et al. Prostate cancer. version 2. 2014. J. Natl. Compr. Canc. Netw. 2014. Vol. 12. No. 5. P. 686-718.
  47. Greco C. Extreme hypofractionated image-guided radiotherapy for prostate cancer. EMJ Oncol. 2013. No. 1. P. 48-55.
  48. Mok G., Benz E., Vallee J.P. et al. Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int. J. Radiat. Biol. Phys. 2014. Vol. 90. No. 2. P. 278-288.
  49. Sumila M., Mack A., Schneider U. et al. Long-term intrafractional motion of the prostate using hydrogel spacer during Cyberknife(R) treatment for prostate cancer a case report. Radiat. 2014. Vol. 9. No. 1. P. 1-6.
  50. Chapet O., Udrescu C., Tanguy R. et al. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy. Int. J. Radiat. Biol. Phys. 2014. Vol. 88. No. 2. P. 425-432.
  51. Wei J.T., Dunn R.L., Litwin M.S. et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000. Vol. 56. No. 6. P. 899-905.
  52. Szymanski K.M., Wei J.T., Dunn R.L. et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring healthrelated quality of life among prostate cancer survivors. Urology. 2010. Vol. 76. No. 5. P. 1245-1250.
  53. King C.R., Collins S., Fuller D. et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int. J. Radiat. Biol. Phys. 2013. Vol. 87. No. 5. P. 939-945.
  54. Arscott W.T., Chen L.N., Wilson N. et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat. 2014. Vol. 9. No. 1. P. 163-172.
  55. Woo J.A., Chen L.N., Bhagat A. et al. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. Fronties in Oncol. 2014. Vol. 4. No. 1. P. 1-10.
  56. Chen L.N., Suy S., Wang H. et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat. 2014. Vol. 9. No. 1. P. 1-9.
  57. Sood S., Ju A.W., Wang H. et al. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat. 2013. Vol. 8. No. 1. P. 1-6.
  58. Kim D.W., Cho L.C., Straka C. et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int. J. Radiat. Biol. Phys. 2014. Vol. 89. No. 3. P. 509-517.
  59. Wiegner E.A., King C.R. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 78. No. 2. P. 442-448.

For citation: Roytberg GE, Usychkin SV, Boiko AV. Extreme Hypofractionated External-Beam Radiotherapy for Prostate Cancer. Medical Radiology and Radiation Safety. 2016;61(1):47-59. Russian.

PDF (RUS) Full-text article (in Russian)

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх